Lv31
290 积分 2022-07-07 加入
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
24天前
已完结
The optimization strategies of LNP-mRNA formulations: Development and challenges for further application
1个月前
已完结
Mediterranean Outflow Mixing and Dynamics
1个月前
已完结
Claudin 18.2 as a novel therapeutic target
1个月前
已完结
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2个月前
已完结
241 Dual targeting liver cancer by GPC3 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen AFP
2个月前
已关闭
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
3个月前
已完结
Autoimmune disease is the next frontier for CAR T cell therapy
4个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
4个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
